Kornimate/medical-research-clean huggingface dataset:
a randomized controlled trial on the efficacy and safety of butylphthalide in reducing myocardial infarction size and improving outcomes in stemi patients after primary pci

Conditions: ST-segment Elevation Myocardial Infarction (STEMI)

Summary: this study is a prospective, randomized, placebo-double-blind, multicenter clinical trial. the purpose of this study is to investigate whether "butylphthalide +pci" combined treatment mode on the basis of traditional drug therapy could reduce myocardial infarct size, improve cardiac function and long-term prognosis of patients with acute myocardial infarction, and verify the drug safety of butylphthalide in the treatment of stemi within the window period of 12 hours.


Eligibility criteria:
inclusion criteria: 1. age range of 18-75 years, encompassing both genders; 2. patients presenting with an initial clinical diagnosis of acute st-segment elevation myocardial infarction (stemi), within a maximum time frame of 12 hours from the onset of pain to consideration for trial inclusion, who fulfill the criteria for percutaneous coronary intervention (pci) and express their intention to undergo pci; 3. the subject and their legal representative possess the capacity and willingness to provide informed consent by signing. exclusion criteria: 1. uncontrolled hypertension (systolic blood pressure≥200mmhg and/or diastolic blood pressure≥110mmhg); 2. previous pci or cabg; 3. long-term use of loading doses of anticoagulant or antiplatelet drugs; 4. history of hemorrhagic stroke or ischemic stroke within 6 months, peptic ulcer, prolonged cardiopulmonary resuscitation (more than 10 minutes) within the last 6 weeks, surgery, or major trauma; 5. known allergy to butylphthalide or excipients; 6. patients with any of the following conditions: cardiogenic shock, chronic congestive heart failure nyha class ≥iii, severe hypotension, pulmonary insufficiency, severe hepatic and renal insufficiency; 7. history of congenital or acquired hemorrhagic diseases, coagulation factor deficiency diseases, thrombocytopenic diseases, etc. or any of the following laboratory tests (inr \> 2.0, platelet count \< 100×109/l, hb \< 10g/dl); 8. pregnancy, lactation, and planning to become pregnant within 30 days; 9. severe mental disorder, alcohol dependence or inability to cooperate with informed consent and follow-up due to dementia; 10. concurrent malignant tumor or severe systemic disease with expected survival time less than 30 days; 11. have participated in or are currently participating in another clinical intervention study within 30 days before randomization; 12. other reasons for not being eligible for the study.
a controlled study of uric acid on the progression of iga nephropathy

Conditions: IgA Nephropathy

Summary: this prospective, randomized controlled study will evaluate the effect of uric acid on the progression of iga nephropathy.

it has been reported that hyperuricemia is a risk factor for progression of igan. this will be a prospective, randomized study. eligible igan patients will be randomized into the treatment group and the control group. patients in treatment group will receive allopurinol and usual therapy. patients in control group will receive usual therapy with placebo. if with hypertension, add the ccb and the β-blocker. fasting uric acid, serum creatinine, albumin, routine blood test, urine microscopy and dipstick, proteinuria of 24 hours and blood pressure will be measured every month. after followed-up for 6 months, the curative effect of allopurinol on blood pressure, proteinuria and the progression of iga nephropathy will be evaluated.

Eligibility criteria:
inclusion criteria: 1. subjects of either sex, more than 18 years old, the range of age is 18 to 70 year old. 2. biopsy-proven iga nephropathy. 3. proteinuria between 0.15g/d and 3.0g/d; and serum albumin level\>3.5g/dl. 4. serum creatinine \< 3 mg/dl. 5. uric acid \> 6 mg//dl (360umol/dl) in female; uric acid \>7mg/dl (420umol/dl ) in male. 6. no history of taking acei or arb within 2 weeks. 7. blood pressure \< 180/110 mmhg. 8. subjects who agree to participate in the study and sign the informed consent. exclusion criteria: 1. patients who have received prednisone or immunosuppressive drugs within 2 months. 2. patients who must take acei or arb due to other diseases. 3. patients who have the history of allergy to allopurinol. 4. unwillingness to follow the study protocol. 5. active gout within 4 weeks. 6. pregnancy or unwillingness to use contraception.

Keywords: iga nephropathy
a study of gefapixant (mk-7264) in adult participants with chronic cough (mk-7264-030)-china extension

Conditions: Chronic Cough

Summary: the primary objective of this study will be to evaluate the efficacy of gefapixant (mk-7264) in reducing cough frequency as measured over a 24-hour period. it is hypothesized that at least one dose of gefapixant is superior to placebo in reducing coughs per hour (over 24 hours) at week 24.

this study will have a main 24-week treatment period and a 28-week extension period of treatment. participants at selected sites and countries who complete the main and extension study periods may consent to participate in an observational, 3-month, off-treatment durability study period.

Eligibility criteria:
inclusion criteria: * chest radiograph or computed tomography scan of the thorax (within 5 years of screening/visit 1 and after the onset of chronic cough) not demonstrating any abnormality considered to be significantly contributing to the chronic cough or any other clinically significant lung disease in the opinion of the principal investigator or the sub-investigator * has had chronic cough for at least 1 year with a diagnosis of refractory chronic cough or unexplained chronic cough * is a female who is not pregnant, not breastfeeding, not of childbearing potential, or agrees to follow contraceptive guidance * provides written informed consent and is willing and able to comply with the study protocol (including use of the digital cough recording device and completion of study questionnaires) exclusion criteria: * is a current smoker or has given up smoking within 12 months of screening, or is a former smoker with greater than 20 pack-years * has a history of respiratory tract infection or recent clinically significant change in pulmonary status * has a history of chronic bronchitis * is currently taking an angiotensin converting enzyme inhibitor (acei), or has used an acei within 3 months of screening * has an estimated glomerular filtration rate (egfr) \<30 ml/min/1.73 m\^2 at screening or an egfr ≥30 ml/min/1.73 m\^2 and \<50 ml/min/1.73 m\^2 at screening with unstable renal function * has a history of malignancy \<=5 years * is a user of recreational or illicit drugs or has had a recent history of drug or alcohol abuse or dependence * has a history of anaphylaxis or cutaneous adverse drug reaction (with or without systemic symptoms) to sulfonamide antibiotics or other sulfonamide-containing drugs * has a known allergy/sensitivity or contraindication to gefapixant * has donated or lost \>=1 unit of blood within 8 weeks prior to the first dose of gefapixant * has previously received gefapixant or is currently participating in or has participated in an interventional clinical study
acoart btk renew：a post market clinical study

Conditions: Peripheral Artery Disease

Summary: the objective of this prospective, multi-center, single arm study is to obtain further data on the safety and performance of the acotec litos\&tulip drug-coated balloon catheters in the treatment of lesions in below-the-knee artery.


Eligibility criteria:
inclusion criteria: * 1. age ≥18 years old and ≤75 years old * 2. rutherford clinical category classification：3,4 or 5 * 3. significant stenosis (≥70%) or occlusions of de-novo or restenotic lesion(s) located in below-the-knee arteries which distal bloodflow is patent. * 4. reference vessel diameter is between 2 mm and 4 mm * 5. subject has provided written informed consent prior to participation , understands the purpose of this trail and agrees to comply with all protocol-specified examinations and follow-up appointments. exclusion criteria: * 1. plasma creatinine clearance rate \<30 ml/min * 2. acute vessel occlusion or acute thrombosis in target lesion * 3. planned amputation on the target limb * 4. subjects confined to bed that are completely non-ambulatory. * 5. thrombolytic therapy or surgical procedure on the target limb within 6 weeks prior to enrollment. * 6. life expectancy \< 5 year. * 7. cumulative length of 100% occluded target lesion(s)\>150 mm * 8. in-stent restenosis within the target lesion, or the distance between the target lesions and the stent was less than 20 mm * 9. history of stroke within 90 days prior to enrollment * 10. known allergy to contrast agents, antiplatelet, anticoagulant, or thrombolytic therapy * 11. uncorrectable bleeding diathesis * 12. the lesion of the inflow pathway cannot be identified due to the complete occlusion of the p3 segment of the popliteal artery * 13. pregnant or breastfeeding female subjects * 14. ability to cross a guidewire through target lesion * 15. patients who have participated in clinical trials of other medical devices or drugs during the same period
gentulizumab in patients with advanced solid malignancies and non-hodgkin lymphoma

Conditions: Solid Tumor; Non-Hodgkin Lymphoma

Summary: the purpose of this study is to assess the safety and tolerability of gentulizumab, an anti-cd47 monoclonal antibody, in participants with solid tumors and non-hodgkin lymphoma.

this is a first-in-human, escalating dose trial of an antibody that inhibits an anti-apoptotic signal in human macrophages. the major aims of the study are to define the safety profile of this new drug, and to determine a recommended dose and schedule for potential additional trials.

Eligibility criteria:
inclusion criteria: * the patient has the willingness to communicate with the investigator, can understand and follow the trial requirements, is willing to participate in the trial, understands and signs a written informed consent form（icf）, and is willing and able to comply with the visit schedule, administration plan, laboratory examination, and other clinical trial procedures. * gender: male or female. * age 18-70 years old. * expected survival ≥ 12 weeks. * patients with eastern cooperative oncology group (ecog) performance status of 0 to 2. * patients with advanced solid tumors or nhl by histopathological diagnosis do not have acceptable standard treatment currently. * adequate organ function per protocol-defined criteria. exclusion criteria: * use of protocol-defined prior/concomitant therapy. * currently receiving or has received an investigational treatment as part of a study within 4 weeks before the first dosing. * history of severe hypersensitivity reaction to study treatments or their excipients. * known active central nervous system metastases. * history of any active autoimmune disease history, or disease or syndrome requiring treatment with systemic steroids or immunosuppressive medications. * presence of active infection. * known additional malignancy that has not been cured in the last 5 years. * any uncontrolled intercurrent illness or condition that in the judgment of the investigator may endanger the patient.
effectiveness of dry needling and stm on pain management for aclr

Conditions: Pain and Anterior Cruciate Ligament Reconstruction

Summary: the purpose of this study is to determine if dry needling (dn) and soft tissue mobilization (stm) is superior to standard treatment protocol for affecting pain, pain medication usage and measurements of range of motion (rom) after acl reconstruction surgery compared to a standard treatment protocol. measurements of pain, pain medication usage, lower extremity functional scale (lefs) and rom will be taken day 2 post op and 1 week, 2 weeks, 3 weeks, and 4 weeks post op. it is hypothesized that the inclusion of dn and stm will acutely decrease the demand for pain medication and improve objective measurements when compared to a standard treatment protocol. findings will potentially lead to insights as to the benefit of applying these interventions to help decrease the demand for pain medication post-surgery.


Eligibility criteria:
inclusion criteria: * age 18-40 department of defense( dod) beneficiaries (17 if cadet) * scheduled for acl reconstruction surgery exclusion criteria: * self-reported pregnancy * history of blood borne pathogens/infectious disease/active infection/metal allergy * bleeding disorders or currently taking anti-coagulant medications * participants who are not fluent in english

Keywords: dry needling acl reconstruction knee rom pain management opioid use
human metabolic dynamics at rest and during aerobic exercise under normobaric normoxic and moderate hypoxic conditions

Conditions: Energy Metabolism; Hypoxia; Metabolism and Nutrition Disorder

Summary: the aim is to define in detail metabolic pathways at rest and during aerobic exercise in normal and healthy men and women under normobaric normoxic and moderate hypoxic conditions, using metabolomics technologies based on minimally invasive sampling relying on gas chromatography and mass spectrometry.


Eligibility criteria:
inclusion criteria: * approval and written, informed consent * healthy adults of varying fitness levels (age \>18 years to 75 years) exclusion criteria: * chronic illness requiring any medication * pregnancy * limitations regarding functioning in the hypoxic chamber * inability to follow simple instructions * relevant or severe abnormalities in medical history, physical examination, ecg routine laboratory parameters from blood and urine
continue vs. stop p2y12 inhibitor on bleeding in patient receiving dapt undergoing dental procedure.

Conditions: Dental Diseases; Antiplatelet Agents; Antiplatelet Drugs

Summary: this is a prospective randomized open-label blinded endpoint (probe) the study will be conducted in maharaj nakorn chiang mai hospital. the patients with dual-antipletlet who need dental procedure between febuary 2017 until febuary 2018 will be included in the study. baseline characteristics of the enrolled patients including bleeding complication will be collected in each patient. to compare rate of significant bleeding from dental procedure between patient who need two antiplatelet and who stop p2y12 inhibitors before procedure.

treatment of coronary artery disease is re-open the occluded artery by many ways such as removed clot and coronary stenting. which needed two antiplatelet after the procedure at least a month to a year. some patient must have life long period to prevent the stent occlude and stenosis. but dental problem is commonly found in real life practice. many people suffered from toothache and have to wait until a year, just to prevent bleeding. physicians often be consulted with this dilemma. to continue there are some risk to bleed but discontinue antipletlet can cause recurrent myocardial ischemia. which the highest risk factor of stent thrombosis is early stop anti platelet. since there is no clinical practice guideline in thailand, this study is to compare rate of dental bleeding between patient who continue two antoplatelet and who stop only p2y12 inhibitor. the study include immediate bleeding, 24 hour and a week after procedure, follow up for major cardiovascular event such as myocardial ischemia, stroke and death. in order to create further clinical practice for this specific group.

Eligibility criteria:
inclusion criteria: * age \>18 years. * need dapt * need to ybeperform dental procedure such as simple extraction, complex extraction, and also focal, multifocal and total gingival scaling exclusion criteria: * patient with coagulopathy * patient with hemophilia * patient with cirrhosis and renal pailure( bun \> 60, cr \> 6.0) * patient who unable to come for medical visit in emergency condition such as severe bleeding * patient with severe disease eg. advance stage cancer. * patient with history of acs less than 6 month * patient who was be pci wit desless than 6 month * patient with dapt but planned to be cabg within a year. * patient with anticoagulant * patient who've got bisphosphonate within 2 years

Keywords: dual antiplatelet therapy dental procedure
assessing the experience of patients undergoing follicular lymphoma clinical research

Conditions: Follicular Lymphoma

Summary: historically, participation in medical studies is highly skewed towards particular demographic groups of people. this research will invite several participants to gather a wide range of information on clinical trial experiences for follicular lymphoma patients. the aim of the study is to identify the factors that limit the ability of a person to enroll in, as well as complete a clinical trial for treatment of follicular lymphoma. the data collected from this study will help improve future outcomes for all follicular lymphoma patients as well as those in under-represented demographic groups.


Eligibility criteria:
inclusion criteria: * participant must be 18 years of age or older * patient has been diagnosed with follicular lymphoma * patient has access to a home internet connection in order to provide regular updates through the course of the study exclusion criteria: * women of childbearing potential without a negative pregnancy test; or women who are lactating. * inability to provide written informed consent * patients receiving any other investigational agents

Keywords: follicular lymphoma
dental loupes in pediatric dentistry practice affect ergonomic posture

Conditions: Ergonomics; Musculoskeletal Diseases; Pediatric Dentistry

Summary: this study aims to investigate the effect of wearing dl on the working posture of pediatric dentists.

in pulpotomy procedures performed with dl in 23 patients and without dl in 23 patients, photographs will taken at a total of 3 times in each patient: at the beginning of the procedure, 15th and 30th minutes. the working postures of the clinicians will analyzed using the modified-dental operator posture assessment instrument (m-dopai) method through these photographs.

Eligibility criteria:
inclusion criteria: * indication for pulpotomy in the mandibular right second primary molar, * 3 (positive)- 4 (definitely positive) according to the frankl behavior scale, * parents volunteered to participate in the study and signed the informed consent form, * did not have any systemic disease or disability. exclusion criteria: * contraindication for pulpotomy in the mandibular right second primary molar * 2 (negative)- 1 (definitely negative) according to the frankl behavior scale
safety and tolerability of the japanese encephalitis vaccine ic51

Conditions: Japanese Encephalitis

Summary: the objective is to investigate the safety and tolerability of japanese encephalitis vaccine ic51 with an inactive control in healthy subjects aged \> or = 18 years


Eligibility criteria:
inclusion criteria: * at least 18 years of age * written informed consent obtained prior to study entry exclusion criteria: * use of any other investigational or non-registered drug or vaccine in addition to the study vaccine during the study period or within 30 days preceding the first dose of study vaccine * history of any previous je vaccination (e.g. je-vax®) * immunodeficiency including post-organ-transplantation or immunosuppressive therapy * a family history of congenital or hereditary immunodeficiency * history of autoimmune disease * any acute infections within 2 weeks prior to enrollment * known or suspected hiv infection * pregnancy, lactation or unreliable contraception in female subjects
management of patients with hepatitis c in a public health care setting: the punjab model

Conditions: Chronic Hepatitis c

Summary: background and aims: the prevalence of hepatitis c virus infection (hcv) infection in punjab, india is 3.29%, with an estimated burden of around 650,000 viremic chronic hcv (chc) patients. the mukh mantri punjab hepatitis c relief fund (mmphcrf) was launched in june 2016 to provide free treatment to all chc aiming to eliminate hcv from punjab. the study assessed the feasibility of decentralized care and efficacy and safety of 12 or 24 weeks of sofosbuvir (sof) + ledipasvir (ldv) or sof + daclatasvir (dcv) ± ribavirin (rbv) in the treatment of chc patients in a public health care setting.

an algorithm was developed using sof-based regimens to treat all patients (rkd). genotyping is not recommended for patients without cirrhosis of liver and they are being treated with sof+dcv for 12-weeks, while genotyping is recommended for patients with cirrhosis of liver (figure 1). patients with liver cirrhosis and genotype 3 are being treated with sof+dcv+rbv for 24 weeks, while non-genotype 3 patients are being treated with sof+ldv+rbv for 12-weeks or with sof+ldv for 24-weeks (in rbv intolerant patients). svr-12 is mandatory in all patients. methods: decentralized care: all patients are being evaluated and treated at 3 government medical colleges and 22 district hospitals; they were followed up to 12 weeks post-treatment to look for sustained viral response (svr-12). health care worker capacity building: 90 medical specialists were trained in a 4-hr predefined course, followed by online continued medical education sessions by regular extension for community healthcare outcomes (echo) clinic are being conducted fortnightly. 50 pharmacists, 2 from each of the 25 centres, dispense medicine as per specialist prescription. data management: 25 trained data entry operators and clinton health access initiative (chai) are managing epidemiological data on chc hotspots, high-risk groups, local service providers, etc. monitoring: medical alerts are being used for compliance monitoring. study design: a cost-effective algorithm has been developed using sof-based regimens to treat all patients. the diagnosis of cirrhosis is based on clinical evidence including aspartate transaminase (ast)-to-platelet ratio index (apri ≥ 2.0) and fib-4 score (\>3.25) or on liver stiffness measurement (lsm) ≥12.5 kilopascal (kpa) on fibroscan. the study aims to validate the efficacy and safety of generic all oral direct acting antiviral (daa) regimens in a decentralized algorithm based public health model in punjab, india regardless of genotype/presence of cirrhosis.

Eligibility criteria:
inclusion criteria: * chronic hepatitis c * age: \>18 years exclusion criteria: * chronic liver disease of a non-hcv etiology * serum creatinine \>1.5 mg/dl * evidence of hepatocellular carcinoma or other malignancy * significant cardiovascular, pulmonary, or neurological disease * history of solid organ or bone marrow transplantation.

Keywords: mukh mantri punjab hepatitis c relief fund,mmphcrf direct antivirals, daas chronic hepatitis c